Developing a new liposome-based adjuvant for vaccines against SARS coronavirus
Official title: ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
Funded at Vaccine Formulation Institute (Ch) LTD · NIH-10935820 · Data updated 2026-11-12
This study is working on a new, affordable ingredient to make vaccines stronger and more effective against certain viruses, with the hope that it will help create better vaccines for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaccine Formulation Institute (Ch) LTD NIH-funded |
| Lab location | 1 site (Plan-Les-Ouates, Switzerland) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2023 |
| Award (this year) | $1,449,048 |
| NIH project number | 75N93023C00048-0-9999-1 |
| Project ID | NIH-10935820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk of SARS coronavirus infections and those involved in vaccine development.
✕Less likely to help
Patients who are not at risk for SARS coronavirus or related infections may not receive direct benefits from this research.
What this research studies
This research focuses on creating a new vaccine adjuvant that enhances immune responses and is cost-effective for vaccine development. It involves formulating a saponin fraction within a liposome carrier to improve the efficacy of vaccines targeting pan-sarbecoviruses. The project includes extensive preclinical evaluations to assess the safety and immunogenicity of the adjuvant, with the goal of making it widely available to the vaccine community. Ultimately, this work aims to facilitate the development of vaccines that can have a significant impact on global health.
Why it matters
Potential benefit: If successful, this research could lead to more effective and affordable vaccines against SARS coronavirus and related viruses.
How similar studies have gone: Other research has shown promise in developing effective adjuvants, but this specific approach using a liposome-based formulation is innovative and relatively untested.
Where this research is happening
-
Vaccine Formulation Institute (Ch) LTD
Plan-Les-Ouates, Switzerland Active
Researchers
- Principal investigator: Collins, Nicolas — Vaccine Formulation Institute (Ch) LTD
- Study coordinator: Collins, Nicolas
Related research
Other NIH-funded projects on the same topics.
-
Developing new immune system boosters for tuberculosis treatment
This study is exploring new ways to boost the immune system's fight against tuberculosis by testing special compounds that help vaccines work better, and it's aimed at finding treatments that could eventually help people with this condition.
-
Developing a new liposome-based adjuvant for COVID-19 vaccines
This study is working on a new ingredient to boost the effectiveness of COVID-19 vaccines, making them stronger and more affordable, so that more people can benefit from better protection against the virus.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.